Erwin Van Meir, PhD


    Emory University Department of Neurosurgery


    Laboratory for Molecular Neuro-Oncology


    • BS, University of Fribourg, Switzerland, 1984
    • Educational Degree, University of Fribourg, Switzerland, 1985
    • PhD, University of Lausanne, Switzerland, 1989



    • Emory 1% member (recognizes faculty with an NIH grant in the 1st percentile)
    • Emory “MilliPub” club (recognizes faculty with a manuscript with over 1,000 citations)
    • External Advisory Board, P01 Lerner Center, Cleveland Clinic (2012, 2013)
    • External Advisory Board, RTOG brain tumor SPORE, Ohio State University (2011)
    • External consultant UCSF Cancer Center, Evaluation of the Neuro-Oncology program for NCI Center grant renewal (2011)
    • 2010 Takao Hoshino Lecture, UCSF Brain Tumor Center, San Francisco
    • External Advisory Board, Brain Tumor Program, MD Anderson Cancer Center (2010)
    • External consultant Columbia University, Promotion and Tenure Committee (2010)
    • "Founders Award for Research Excellence" from the National Brain Tumor Society to The Cancer Genome Atlas (TCGA) GBM Research Group (Dr Anna Barker recipient)
    • Invention "Small Molecule Modulators of HIF-1 Activity" selected in 2007 at BIO/Plan Competition, Southeast BIO
    • External consultant Univ. Texas Southwestern Medical Ctr., Promotion and Tenure Committee (2007)

    Society Memberships

    • Society for Neuro-Oncology
    • American Association for Cancer Research


    Dr. Van Meir’s research interest lies in understanding the molecular basis for human tumor development and how we can use this knowledge to devise new therapeutics that will improve patient survival. We examine how genetic alterations and hypoxia induce changes in cell biology that promote tumor formation with particular emphasis on heterotypic cell-cell signaling, including tumor angiogenesis. We have developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules, and are currently developing novel small molecule inhibitors of the hypoxia-inducible factor pathway. We aim to translate these novel agents to testing in clinical trials with the hope to develop novel medicines for cancer treatment. The principal modeling systems we use are malignant brain (glioblastoma and medulloblastoma) and eye (metastatic uveal melanoma) cancers, although the experimental therapeutics we develop are applicable to the cure of many solid malignancies.

    For a list of Dr. Van Meir's current funding, click here


    For a complete listing of Dr. Van Meir’s publications and other works, please click the Google Scholar logo.

    Dr Van Meir Google Scholar page